Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-01-02
2007-01-02
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S084000
Reexamination Certificate
active
10344146
ABSTRACT:
The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO2, CH2, C═O or COO; YZ represents a group of formula CH(R25)—CH(R26) or CH(R27)═(R28), and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO2, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixture or their optically pore isomers. The invention also concerns their preparation, pharmaceutical compositions comprising them and their use as CaSR activity modulator and as medicine particularly designed for the treatment of psychological diseases and disorders involving CaSR activity modulation.
REFERENCES:
patent: 3262977 (1966-07-01), Harsanyi et al.
patent: WO 93/04373 (1993-03-01), None
patent: WO 93/04373 (1993-03-01), None
patent: WO 95/11221 (1995-04-01), None
patent: WO 95/11221 (1995-04-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO 98/44925 (1998-10-01), None
patent: WO 98/45255 (1998-10-01), None
patent: WO 99/51241 (1999-10-01), None
patent: WO 99/51569 (1999-10-01), None
Antonsen et al., “A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure”,Kidney International, 1998, pp. 223-227, vol. 53, The International Society of Nephrology.
Brown, “Cloning and characterization of an extracellular Ca2+—sensing receptor from bovine parathyroid”,Nature, Dec. 9, 1993, pp. 575-580, vol. 366.
Brown, “The extracellular calcium sensing receptor: Its Role in Health and Disease”,Annu. Rev. Med., 1998, vol. 49, pp. 15-29, Annual Reviews, Inc.
Chattopadhyay et al., “The Calcium-Sensing Receptor: A Window into the Physiology and Pathophysiology of Mineral Ion Metabolism”,Endocrine Reviews, 1996, vol. 17, No. 4, pp. 289-307, The Endocrine Society, USA.
Ferry et al., “Effects of divalent Cations and of a Calcimimetic on Adrenocorticotropic Hormone Release in Pituitary Tumor Cells”,Biomedical and Biophysical Research Communication, 1997, pp. 866-873, vol. 238, No. 3, Academic Press.
Nageli et al., “81, Rhodium(II)-Catalyzed CH Insertions with {[(4-Nitrophenyl)sufonyl]imino}phenyl-λ3-iodane,”Helvetica Chimica Acta, Jun. 30, 1997, pp. 1087-1105, vol. 80, No. 4, Verlag Helvetica Chimica Acta, Bale, CH.
Nemeth et al., “Calcimimetic Compounds: a Direct Approach to Controlling Plasma Levels of Parathyroid Hormone in Hyperparathyroidism”,TEM, 1999, vol. 10, No. 2, pp. 66-71, Elsevier Science.
Nemeth et al., “Calcimimetics with potent and selective activity on the parathyroid calcium receptor”,Proc. Natl. Acad. Sci., Mar. 1998, pp. 4040-4045, vol. 95, Pharmacology, USA.
Pollak et al., “Autosomal dominant hypocalcaemia caused by a Ca2+—sensing receptor gene mutation”,Nature Genetics, Nov. 1994, pp. 303-307, vol. 8.
Pollak et al., “Mutations in the Human Ca2+-sensing Receptor Gene Cause Familial Hypocalciuric Hypercalcemia and Neanatal Severe Hyperparathyroidism”,Cell, Dec. 31, 1993, pp. 1297-1303, vol. 75, Cell Press.
Ruat et al., “Calcium sensing receptor: Molecular cloning in rat and localization to nerve terminals”,Proc. Natl. Acad. Sci., Apr. 1995, pp. 3161-3165, vol. 92, Neurobiology, USA.
Ruat et al., “Cloned and Expressed Rat Ca2+-sensing Receptor”,The Journal of Biological Chemistry, Mar. 15, 1996, pp. 5972-5975, vol. 271, No. 11, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Schlichter et al., “Asymmetric Reductive Amination of Cycloalkanones, XIII: Enantioselective Amidoamination: A New Regiospecific Strategy for the Synthesis of Chiral Cyclohexane-1,2-diamino-Derivatives,”Arch. Pharm., 1993, vol. 326, No. 7, pp. 429-436, VCH Verlagsgesellschaft, Weinheim, DE.
Schlichter et al., “Novel,Enantioselective Synthesis of Vicinal Cyclohexane-Diamines as Key-Intermediates for Highly Selective Opioid Kappa and Sigma Agonists,”Tetrahedron: Asymmetry, 1992, pp. 3289-3333, vol. 3, No. 3, Elsevier Science Publishers, Amsterdam, NL.
Silverberg et al., “Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in patients with primary hyperparathyroidism”,New England Journal of Medicine, Nov. 20, 1997, pp. 1506-1510, vol. 337, No. 21.
Sodergren et al., “Preparation and Evaluation of Nitrene Precursors (Phl=NSO2Ar) for the Copper-Catalyzed Aziridination of Olefins,”Tetrahedron Letters, Sep. 29, 1997, pp. 6897-6900, vol. 38, No. 39, Elsevier Science Publishers, Amsterdam, NL.
Wada et al., “NPS R-568 halts or reverses osteitis fibrosa in uremic rats”,Kidney International, 1998, pp. 448-453, vol. 53, The International Society of Nephrology.
Wada et al., “The calcimimetic Compound NPS R-568 suppresses Parathyroid Cell Proliferation in Rats with Renal Insufficiency”,J. Clin. Invest., pp. 2977-2983, vol. 100, No. 12, The American Society for Clinical Investigation, Inc.
Ye et al., “Amyloid-B Proteins Activate Ca2+—Permeable Channels Through Calcium-Sensing Receptors”,Journal of Neuroscience Research, 1997, pp. 547-554, vol. 47, Wiley-Liss, Inc.
W. H. Schlichter et al.; “Novel enantioselective synthesis of vicinal cyclohexanediamines as key-intermediates for highly selective opioid kappa and sigma agonists”, Tetrahedron: Asymmetry, vol. 3, No. 3, 1992, pp. 329-333, Elsevier Science Publishers, Amsterdan, NL.
W. H. Schlichter et al., “Asymmetric reductive animation of cycloakanones, XIII. Enantioselective amidoamination: a new regiospecific strategy for the synthesis of chiral cyclohexane-1,2-diamino-derivatives”, Archive Der Pharmazie, vol. 326, No. 7, 1993, pp. 429-436, VCH Verlagsgesellschaft, Weinheim, DE.
Dauban Philippe Marcel
Dodd Robert Hugh
Faure Hélène Véronique
Kessler Albane
Potier Pierre Jean-Paul
Centre National de la Recherche Scientifique "CNRS"
McKane Joseph K.
Shiao Robert
LandOfFree
Diamines having a CaSR modulating activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diamines having a CaSR modulating activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diamines having a CaSR modulating activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724540